These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6145498)

  • 1. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ; Wang RY
    Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of cholecystokinin and dopamine in the nucleus accumbens.
    Wang RY; White FJ; Voigt MM
    Ann N Y Acad Sci; 1985; 448():352-60. PubMed ID: 2862829
    [No Abstract]   [Full Text] [Related]  

  • 7. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.
    Jiang LH; Kasser RJ; Wang RY
    Brain Res; 1988 Nov; 473(1):165-8. PubMed ID: 3208120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro.
    Voigt M; Wang RY; Westfall TC
    J Pharmacol Exp Ther; 1986 Apr; 237(1):147-53. PubMed ID: 3958963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward.
    Vaccarino FJ; Koob GF
    Neurosci Lett; 1984 Nov; 52(1-2):61-6. PubMed ID: 6098878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward.
    Vaccarino FJ; Vaccarino AL
    Neurosci Lett; 1989 Feb; 97(1-2):151-6. PubMed ID: 2918999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin.
    Liang RZ; Wu M; Yim CC; Mogenson GJ
    Brain Res; 1991 Jul; 554(1-2):85-94. PubMed ID: 1681991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons.
    Kelland MD; Zhang J; Chiodo LA; Freeman AS
    Synapse; 1991 Jun; 8(2):137-43. PubMed ID: 1882334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat.
    Debonnel G; de Montigny C
    Synapse; 1988; 2(5):537-45. PubMed ID: 2903570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.